1 Dheda K

Gumbo T

Maartens G

et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis.

2 Furin J

Brigden G

Lessem E

Rich M

Vaughan L

Lynch S Global progress and challenges in implementing new medications for treating multidrug-resistant tuberculosis.

Almost 50 years after the discovery of rifampin, clinicians and tuberculosis programmes finally have treatment options to offer people with rifampin-resistant tuberculosis, which can improve outcomes and limit toxic effects associated with conventional treatment. Such innovations include the newer drugs bedaquiline and delamanid, repurposed drugs such as linezolid or clofazimine, and shorter regimens.Because of limited availability and resources, many programmes, policy makers, and clinicians have had to choose between using bedaquiline or delamanid, but not both.